MDAT
Jump to navigation
Jump to search
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII |
|
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C11H13NO2 |
Molar mass | 191.230 g·mol−1 |
3D model (JSmol) | |
|
6,7-Methylenedioxy-2-aminotetralin (MDAT) is a drug developed in the 1990s by a team at Purdue University led by David E. Nichols.[1] It appears to act as a serotonin releasing agent based on rodent drug discrimination assays comparing it to MDMA, in which it fully substitutes for, and additionally lacks any kind of serotonergic neurotoxicity.[1] Hence, MDAT is considered likely to be a non-neurotoxic, putative entactogen in humans.
See also
References
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Drugs with non-standard legal status
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Multiple chemicals in Infobox drug
- Chemicals using indexlabels
- Chemical articles with multiple CAS registry numbers
- Articles containing unverified chemical infoboxes
- 2-Aminotetralins
- Entactogens and empathogens
- Benzodioxoles
- Designer drugs
- Serotonin releasing agents